3M Health Care Launches New Chromatographic Clarifier
The 3M Harvest RC Chromatographic Clarifier, BT500 is the latest addition to the company’s chromatographic clarifier portfolio.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
On Nov. 15, 2023, 3M announced the latest addition to its chromatographic clarifier portfolio. The Harvest RC Chromatographic Clarifier, BT500 is a 500-mL size, single-use chromatographic clarifier for monoclonal antibodies, recombinant proteins, and biologics. According to the company, the BT500 can produce predictive yield samples in 10 minutes, based on 5–8% packed cell volume (PCV) culture.
The BT500 offers a lab-scale solution for high purity and recovery “representative of a commercial scale process for clarification,” without the need for a centrifuge. The bottle-top vacuum technology delivers high product recoveries and DNA reduction (< 500ppb—based on 5–8% PCV culture) through a streamlined workflow, according to the company.
The 3M Harvest RC Chromatographic Clarifier portfolio is a set of fiber chromatography clarification devices that use proprietary fibrous chromatography media to deliver a single-stage purification solution for recombinant protein therapeutic manufacturing, which streamlines a multi-stage harvest clarification operation into a single-stage operation.
“Adding 3M Harvest RC Chromatographic Clarifier, BT500 to our product portfolio provides a much-needed solution for customers looking to maximize efficiency in the lab setting, allowing them to better keep pace with the accelerated industry demand,” said David Chau, bioprocess applications specialist at 3M Separation and Purification Sciences, in a press release.“ The Harvest RC Chromatographic Clarifier portfolio enables process intensification, yield improvements, and greater contaminant reduction compared to legacy methods. This new rapid testing capability extends even more opportunity for efficient workflows and exceptional clarity in bioprocess manufacturing.”
Source: 3M
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
